Bente Frimodt-Moller

Bente Frimodt-Moller

UNVERIFIED PROFILE

Are you Bente Frimodt-Moller?   Register this Author

Register author
Bente Frimodt-Moller

Bente Frimodt-Moller

Publications by authors named "Bente Frimodt-Moller"

Are you Bente Frimodt-Moller?   Register this Author

7Publications

226Reads

39Profile Views

PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.

J Clin Oncol 2013 Dec 21;31(34):4349-57. Epub 2013 Oct 21.

Jyoti D. Patel, Northwestern University; Philip Bonomi, Rush University Medical Center, Chicago, IL; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; Edward B. Garon, University of California at Los Angeles, Los Angeles, CA; Craig H. Reynolds, US Oncology Research, Ocala, FL; David R. Spigel, Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN; Mark R. Olsen, Tulsa Cancer Institute, Tulsa, OK; Robert C. Hermann, Northwest Georgia Oncology Centers, Marietta, GA; Robert M. Jotte, Rocky Mountain Cancer Centers, Denver, CO; Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Donald A. Richards, US Oncology Research, Tyler, TX; Susan C. Guba, Jingyi Liu, Bente Frimodt-Moller, and William J. John, Eli Lilly, Indianapolis, IN; Coleman K. Obasaju and Eduardo J. Pennella, Lilly USA, Indianapolis, IN; and Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.9626DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881367PMC
December 2013